Merit Medical Systems (MMSI) – Investment Analysts’ Recent Ratings Changes

Merit Medical Systems (NASDAQ: MMSI) has recently received a number of price target changes and ratings updates:

• 2/26/2026 – Merit Medical Systems was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $78.00 price target on the stock, down from $95.00.
• 2/25/2026 – Merit Medical Systems had its price target raised by Barrington Research from $106.00 to $109.00. They now have an “outperform” rating on the stock.
• 2/25/2026 – Merit Medical Systems had its price target lowered by Needham & Company LLC from $108.00 to $101.00. They now have a “buy” rating on the stock.
• 2/18/2026 – Merit Medical Systems had its price target lowered by Piper Sandler from $113.00 to $106.00. They now have an “overweight” rating on the stock.
• 2/6/2026 – Merit Medical Systems is now covered by BTIG Research. They set a “buy” rating and a $107.00 price target on the stock.
• 2/6/2026 – Merit Medical Systems is now covered by BTIG Research. They set a “buy” rating and a $107.00 price target on the stock.
• 1/9/2026 – Merit Medical Systems had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $108.00 price target on the stock.

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.